Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
Beam Therapeutics announced it will present updated Phase 1/2 clinical trial data for ristoglogene autogetemcel (risto-cel), an investigational gene-edited cell therapy aimed at treating sickle cell disease (SCD). The data underscores risto-cel's potential to restore red blood cell health and improve disease pathology by inducing fetal hemoglobin p…